Abstract 2204P
Background
Malignant pleural mesothelioma (MPM) is a rare thoracic malignancy with bad prognosis. Asbestos exposure has been described as the main risk factor with a key role in its pathogenesis. The aim of this study is to identify the impact of systemic inflammation biomarkers as clinical prognostic factors for MPM.
Methods
Patients (pts) diagnosed of MPM from 2004 to 2023 from a Medical Oncology Intercenter Unit in Malaga (Spain) were enrolled. We analyzed epidemiologic, clinical and pathological characteristics and correlated them with survival outcomes.
Results
Among the 140 pts, median age was 70 years (range 23-94), ECOG 0-1 in 76,4% (n=104), mainly males (70,7%, n=99). 95 pts (67,9%) were epithelioid subtype. Median follow up was 21,6 months (mo) (range 1-217). Median overall survival (OS) 13,5 mo (CI 95% 9,6-17,4), progression-free survival (PFS) 10,1 mo (CI 95% 7,2-13). 19 pts (13,6%) were considered for surgery. In non-resectable pts (n=121, 86,4%), age over 65, malnutrition and ECOG 2-4 at diagnosis were associated to poor OS (21,6 mo CI95% 14,4-28,8; 7,1 mo, CI95% 5,8-8,2; 4,7 mo, CI95% 3-6,5 respectively). Inflammatory biomarkers including high LDH or CRP, neutrophilia, Lung Immune Prognostic Index (LIPI) intermediate-poor, and high dNLR suggested a trend towards poor survival (9,5 mo CI 95% 3,5-15,4; 8,5 mo CI 95% 4,5-12,5; 7,1 mo CI 95% 1,5-3,9; 9,5 mo CI95% 4,5-14,4; 9,5 mo CI95% 4,8-14, respectively; p>0.5). Anemia, moderate-to-severe value of neutrophil to lymphocyte ratio (NLR≥6) and not receiving immunotherapy were significantly associated with worse prognosis. Multivariate analysis showed age and NLR value as independent prognostic factors (p<0.01).
Conclusions
Host inflammation status at diagnosis may be a subrogate biomarker of survival for MPM, even for pts not receiving immunotherapy. Modulating the immune system and inflammatory pathways appear as promising strategies for increasing effectiveness in MPM treatment. Table: 2204P
Univariate analysis | Multivariate analysis | |||||
HR | CI 95% | P | HR | CI 95% | P | |
Age ≤65 | 0,56 | 0,36-0,88 | 0,01 | 0,44 | 0,23-0,82 | 0,01 |
ECOG | 1,65 | 1,3-2,6 | 0,00 | - | - | 0,37 |
Malnutrition | 0,47 | 0,29-0,74 | 0,00 | - | - | 0,78 |
Anemia | 9,86 | 0,76-0,96 | 0,01 | - | - | 0,29 |
High C reactive protein | 1,87 | 0,77-4,52 | 0,16 | - | - | - |
Neutrophilia | 2,38 | 0,31-18,41 | 0,40 | - | - | - |
High LDH | 1,47 | 0,93-2,34 | 0,09 | - | - | - |
NLR (absent-mild vs moderate severe) | 0,5 | 0,28-0,90 | 0,02 | 0,30 | 0,14-0,61 | 0,00 |
dLNR (high vs normal) | 0,91 | 0,58-1,42 | 0,69 | - | - | - |
LIPI score (good vs intermediate-poor) | 1,47 | 0,96-2,27 | 0,07 | - | - | - |
Immunotherapy | 0,48 | 0,24-0,96 | 0,04 | - | - | 0,62 |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2247P - Expression of PD-L1 on circulating epithelial tumor cells (CETCs) in men with primary non-metastatic prostate cancer
Presenter: Dorothea Schott
Session: Poster session 07
2248P - Capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer (PANDORA trial): Molecular profiling and translational results
Presenter: Stefano Tamberi
Session: Poster session 07
2249P - Mitigation of tumor microenvironment-mediated immunosuppression using a PD1-41BB switch protein with optimal affinity tcrs for first-in-class, 3rd generation TCR-T therapies
Presenter: Kirsty Crame
Session: Poster session 07
2250P - Exploring tumor microenvironment in lung cancer through patient-derived 3D models
Presenter: NORA JUCIUTE
Session: Poster session 07
2251P - The genomic landscape of radiotherapy-induced breast angiosarcoma: An alleanza contro il cancro (ACC) initiative for an unmet need in rare tumors
Presenter: Lorenzo Ferrando
Session: Poster session 07